Back to mobile site

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. MRNA
2. PANW
3. KEYS
4. MRK
5. KLAR
6. TGT
7. LOW
8. UBER
9. SPY
10. BIDU

April 19, 2023 7:00 AM EDT

TEL AVIV, Israel, April 19, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in a number of scientific conferences in April and May.

British Society for Rheumatology Annual Conference – April 24-26, 2023

Date:       

April 24, 2023

Time:       

9:45am BST

Venue: 

Manchester Central Convention Complex, Manchester, UK and virtual

Format:       

Oral presentation: CCL24 Serum Concentration Predicts Both Vascular and Fibrotic Complications in Systemic Sclerosis: Rationale for a Biological Target Driven, Basket Trial Across Disease Subsets

Presenter:   

Professor Enrico De Lorenzis, Leeds Institute of Rheumatic and Musculoskeletal Diseases, University of Leeds, UK

Information: 

https://www.rheumatology.org.uk/events-learning/conferences/annual-conference 

EASL Monothematic Conference on Biliary Fibrosis 2023 – May 12-13, 2023

Date:         

May 12, 2023

Time:         

17:20-17:50 CEST

Venue:         

Grand Hotel Baglioni, Florence, Italy

Format:       

Poster presentation: Patient proteomic data and mouse model reinforce the proinflammatory role of CCL24 in cholestatic disease

Session:       

ePoster session 3 and break

Presenter:     

Matt Frankel, MD, Chief Medical Officer, Chemomab

Information: 

https://easl.eu/event/biliary-fibrosis-23/ 

In addition, Chemomab's corporate development team will be in Boston June 5-8, 2023, participating in the BIO International Convention's One-on-One Partnering™ event. Registered attendees can click here to log in and schedule a meeting with Chemomab.

About Chemomab Therapeutics

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin around midyear. For more information on Chemomab, visit chemomab.com.

Contacts:

Investors: 

Investors & Media:

Irina Koffler                                         

Barbara Lindheim

LifeSci Advisors, LLC                           

Chemomab Therapeutics

Phone: +1 (917) 734-7387                   

Consulting Vice President, Investor & Public Relations

[email protected]                               

Strategic Communications


[email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-upcoming-scientific-conferences-301801509.html

SOURCE Chemomab Therapeutics, Ltd.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

PRNewswire, Press Releases

Related Entities

Irina Koffler